Trial Profile
Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Ficlatuzumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 01 Aug 2021 Status changed from active, no longer recruiting to completed.
- 02 Mar 2021 Planned End Date changed from 30 Nov 2023 to 1 Oct 2023.
- 02 Mar 2021 Planned primary completion date changed from 30 Nov 2020 to 10 Oct 2020.